Atrophic vaginitis is typically associated with the hypoestrogenic state of menopause. However, lactation also decreases estrogen levels and can cause symptomatic urogenital atrophy. Discussion of ...

Vaginal atrophy is a condition that can negatively impact the quality of life of many postmenopausal women. Local exogenous estrogen therapy can effectively alter the anatomic and pathophysiologic ...

Bachmann G, Lobo RA, Gut R, Nachtigall L, Notelovitz M. Efficacy of low-dose estradiol vaginal tablets in the treatment of atrophic vaginitis: a randomized controlled trial. Obstet Gynecol 2008;111:67 ...

A session at the recent Nurse Practitioners in Women's Health annual conference focused on vulvovaginal changes that occur during menopause, the effects of atrophic vaginitis on postmenopausal women, ...

(MENAFN- EIN Presswire) EINPresswire/ -- The Atrophic Vaginitis Treatment Market was valued at USD 1.2 billion in 2024 and is projected to reach USD 2.5 billion by 2034, registering a CAGR of 7.5%.

Please provide your email address to receive an email when new articles are posted on . At 12 weeks, vaginal hyaluronic acid and vaginal estrogen were associated with genitourinary syndrome of ...

Several postmenopausal patients with desquamative inflammatory vaginitis (DIV) would prefer to receive all their treatments at our office before seeing a specialist. Unfortunately, I cannot find much ...

The Food and Drug Administration has approved Aubobindo’s estradiol vaginal inserts, 10 mcg, which is the generic of Novo Nordisk’s Vagifem. The product will be launched in the second quarter of 2025.